SCHEMBL3410116

SCHEMBL3410116

CN1CCC(NC(=O)Nc2ccc3nc(NC4COc5ccccc54)ccc3c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 6/20 0.46
EPHX2 P34913 2/20 0.44
CXCR3 P49682 2/20 0.43
PTPN7 P35236 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
HSPA1A P0DMV8 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
HPGD P15428 1/20 0.40
TNNI3 P19429 1/20 0.40
APEX1 P27695 1/20 0.40
TNNT2 P45379 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40
TNNC1 P63316 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3408455 0.86 EPHX2 (0.46) EPHX2CXCR3MEN1ALDH1A1MAPT
SCHEMBL3414720 0.82 NPY1R (0.45) TRPV1KDM4EMEN1TP53POLB
SCHEMBL3415718 0.78 MAPT (0.44) EPHX2ALDH1A1MAPTSMN1; SMN2MALT1
SCHEMBL3412407 0.78 JAK2 (0.47) EPHX2PTPN7KDM4EMEN1ALDH1A1
SCHEMBL3410853 0.78 ALDH1A1 (0.51) EPHX2CXCR3KDM4EMEN1ALDH1A1
SCHEMBL3415079 0.78 EPHX2 (0.42) EPHX2CXCR3KDM4EMEN1ALDH1A1
SCHEMBL3413459 0.77 EPHX2 (0.47) EPHX2CXCR3MEN1ALDH1A1MAPT
SCHEMBL3414458 0.77 CXCR3 (0.49) EPHX2CXCR3KDM4EMEN1ALDH1A1
SCHEMBL3411542 0.77 NPC1 (0.41) TRPV1EPHX2MEN1ALDH1A1MAPT
SCHEMBL3411547 0.77 NPC1 (0.41) TRPV1EPHX2MEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183380-B2 2-aminoquinolines HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US claimed
EP-2262789-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-12-22 EP claimed
WO-2009109477-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO claimed
US-20090227570-A1 2-AMINOQUINOLINES HOFFMANN-LA ROCHE, INC. 2009-09-10 US claimed
US-8183380-B2 2-aminoquinolines HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
EP-2262789-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-12-22 EP disclosed
WO-2009109477-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO disclosed
US-20090227570-A1 2-AMINOQUINOLINES HOFFMANN-LA ROCHE, INC. 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227570-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2A TRPV1 379/4885EPHX2 2067/4885CXCR3 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.